Key Highlights

  • Organogenesis shares fell approximately 20.12 percent in pre-market trading to $1.93 from Wednesday's close of $2.41.
  • Second quarter net product revenue fell 58 percent year over year to $42.8 million, with advanced wound care sales down 61 percent.
  • The company reported a wider net loss and cut full-year 2026 revenue guidance to $179 million to $215 million.
  • Gross margin deteriorated to 45 percent on a non-GAAP basis, down from 68 percent a year earlier.

Wound Care Decline Deepens

Organogenesis Holdings Inc. (NASDAQ:ORGO) traded down approximately 20.12 percent in pre-market activity, near $1.93 versus Wednesday's close of $2.41. Second quarter net product revenue fell 58 percent year over year to $42.8 million, with advanced wound care sales declining 61 percent, even as total revenue rose 18 percent sequentially.

Profitability Pressured

Gross margin deteriorated sharply to 45 percent on a non-GAAP basis from 68 percent a year earlier, with an operating loss of $51 million and a GAAP net loss of $96.3 million, which included a $30 million non-cash tax charge. Adjusted EBITDA loss widened to $34.4 million.

Restructuring Continues as Guidance Is Cut

The company completed a second 2026 restructuring in June, with total annualized savings now exceeding $32 million, while cash fell to $46.3 million from $94.3 million at year-end 2025. Full-year revenue guidance was revised to $179 million to $215 million from a prior $210 million to $215 million.

Cost Cuts and Pipeline Offer Some Support

Operating expenses excluding cost of goods sold are expected to decline about 32 percent year over year in 2026. Management pointed to a BLA target date of April 2027 for Inuvik, while Dermagraft manufacturing has been delayed into mid-2028 to preserve cash.

Conclusion

Organogenesis' sharp decline reflects a business navigating a significant wound care contraction alongside deteriorating margins and a guidance cut, even as sequential improvement and cost reductions offer some evidence of stabilization. The path back to growth appears tied more to pipeline milestone timing than any near-term recovery in core wound care.